Artificial neural network as a strategy to predict rheological properties in emulgel formulations

Breaking: AI Transforming Pharmaceutical Rione: Breakthroughs Rattle Drug Discovery, Delivery and Regulation

Artificial intelligence in pharmaceutical progress is accelerating breakthroughs across the value chain, from molecule design to delivery and stability testing. In the past year, scientific reviews and policy discussions have emphasized how AI is reshaping how medicines are discovered, formulated, and brought to patients.

Industry experts say the wave of new research confirms a lasting shift. AI is now routinely cited as a driver of personalized medicine, smarter formulation, and predictive analytics that speed up development timelines while reducing trial-and-error work.

What the studies are showing

Across 2024 and 2025, peer-reviewed analyses and reviews highlighted several durable trends. AI-driven techniques are increasingly being applied to drug delivery systems, enabling more efficient design and optimization of nanoparticle carriers and other advanced formulations. In parallel,researchers report AI models predicting key formulation properties,from disintegration times to tablet hardness,to forecast performance before costly experiments.

Analyses also underscored AI’s role in understanding and predicting complex rheological behavior in hydrogel-based materials, which are instrumental in controlled release and topical therapies. Among the moast prominent themes is a shift toward data-driven design that aligns with quality-by-design principles, aiming to reduce variability and increase reproducibility in pharmaceutical development.

Regulatory and governance discussions have kept pace. A major U.S. goverment agency published a discussion paper in 2025 outlining how AI and machine learning can be integrated into drug development, emphasizing transparency, validation, and safety as central requirements. Industry voices stress the need for robust frameworks so AI tools reliably support decision-making without compromising patient safety.

Key AI tools and domains reshaping pharma

recent studies map AI impact across several critical domains:

• Drug discovery and precision medicine: AI accelerates the exploration of candidate molecules and tailoring therapies to individual patients.
• Drug delivery systems: AI-driven design and optimization of nanoparticle-based carriers and related delivery platforms.
• pre-formulation and formulation analytics: machine learning predicts solubility, stability, and other formulation properties to guide formulation choices.
• Hydrogel and rheology prediction: Data-driven models forecast the flow and deformation properties of gels used in topical and implantable therapies.
• Stability forecasting: predictive analytics help anticipate stability under various storage conditions, reducing late-stage surprises.
• In silico distribution and pharmacokinetics: Computational models simulate how drugs disperse in the body to inform dosing strategies.

These findings are echoed by recent reviews and research articles, which collectively point to AI as a catalyst for faster, more reliable development pathways and more personalized therapies.

Table: AI applications in pharmaceutical development

Request Area	What AI Does	Key Trends	Representative Milestones
Drug Discovery & Personalization	Generates and optimizes candidate molecules; individualizes therapies	Increased use of AI in discovery pipelines; emphasis on patient-specific treatment approaches	numerous 2024–2025 reviews highlighting AI-driven discovery and personalized medicine
Drug Delivery Systems	Designs and optimizes carrier technologies (e.g., nanoparticles)	AI-guided nanoparticle design and release profiling	2024–2025 studies on AI-driven nanoparticle delivery optimization
Formulation & Pre-formulation	Predicts solubility, stability, and other formulation properties	Predictive modeling reduces experimental iterations	AI-based prediction models for disintegration time and tablet hardness (2024–2025)
Hydrogel Rheology	Forecasts rheological properties of hydrogels and emulgels	Data-driven rheology predictions enable better materials design	Hydrogel-focused ML studies published 2023–2025
Stability & PK Modeling	Predicts stability outcomes and distribution kinetics	Predictive analytics streamline stability testing and PK planning	stability analytics and in silico distribution papers 2024–2025

External sources and policy updates bolster this view. A 2025 federal discussion paper from the U.S.regulatory authority emphasizes responsible AI use in drug development, calling for rigorous validation and safety assurances. Meanwhile, reviews in high-profile journals reinforce AI’s expanding footprint across therapeutic areas and delivery platforms.

What this means for patients and the industry

For patients, AI promises faster development of targeted therapies with improved predictability and safety. For the industry, the message is clear: leveraging AI can shorten timelines, cut costs, and enable more nuanced formulation and delivery strategies. Experts caution that AI tools must be deployed with transparent validation, robust data governance, and clear lines of responsibility to maintain trust and safety.

In the near term, expect continued integration of AI in regulatory-ready workflows, with more emphasis on explainable models and standardized validation protocols. As datasets grow and computational methods mature, AI could help standardize processes across manufacturers, supporting better quality, consistency, and efficiency in drug development.

Disclaimer: This article is for informational purposes and does not constitute medical or legal advice.

Evergreen takeaways

– AI in pharmaceutical development is no longer experimental; it’s becoming a core tool in discovery, formulation, and delivery.

– The strongest momentum sits at the intersection of AI-driven design, data governance, and regulatory alignment to ensure safety and efficacy.

– Ongoing research across 2023–2025 highlights tangible gains in predicting rheology, stability, and PK behavior, helping teams make smarter, faster decisions.

Two quick questions for readers: Which AI application excites you most in the pharma space—precision medicine, smarter delivery systems, or predictive formulation—and why? How should regulators balance innovation with safety as AI becomes more embedded in drug development?

For more context, you can explore official regulatory discussions on AI in drug development and recent reviews of AI applications in drug delivery and personalized medicine by visiting these authoritative sources:
– FDA’s AI and ML in drug development discussion paper (2025).

– Reviews on AI-driven design and optimization of nanoparticle delivery systems (2024).

Share this breaking update and join the conversation: what AI-driven advances in pharmaceuticals will impact you the most in the next year?

Key keyword focus: AI in pharmaceutical development

Categorical surfactant types are present.

---

Understanding Rheological Parameters in Emulgel Formulations

• Viscosity – measures resistance to flow; critical for spreadability and drug release.
• Yield stress – the minimum stress required to initiate movement; influences product stability.
• Thixotropy – time‑dependent shear thinning; determines how the gel regains structure after submission.
• Elastic modulus (G’) and viscous modulus (G’’) – describe the balance between solid‑like and liquid‑like behavior, directly impacting texture perception.

Accurate prediction of these parameters accelerates formulation growth, reduces experimental trials, and supports regulatory submissions.

---

Why Artificial Neural Networks (ANNs) outperform Traditional Models

1. Non‑linear pattern recognition – Rheology of emulgels involves complex interactions among surfactants, polymers, and dispersed phases; ANNs capture these relationships without linear assumptions.
2. Adaptability to high‑dimensional data – Variables such as temperature, pH, oil‑to‑water ratio, and polymer molecular weight can be processed simultaneously.
3. Robustness to noisy experimental data – With proper regularization, ANNs filter out experimental variability, delivering reliable predictions.

Recent literature (e.g., Liu et al., 2023; Singh & Patel, 2022) demonstrates ANN prediction errors as low as 3 % for viscosity compared to 12 % for multiple linear regression.

---

preparing a Quality Dataset

Step	action	Best‑Practise tips
1	Experimental design – Use a factorial design (e.g., Box‑Behnken) to cover the full compositional space.	Include at least 3 replicates per condition to capture variability.
2	Feature selection – Record composition (oil %,surfactant type,polymer concentration),processing parameters (mixing speed,temperature),and physicochemical descriptors (HLB value,polymer Mw).	Perform correlation analysis; discard features with variance inflation factor > 5.
3	Data cleaning – Remove outliers beyond 1.5 × IQR or flagged by Mahalanobis distance.	Document removal rationale for audit trails.
4	Normalization – Apply Min‑Max scaling (0–1) or Z‑score standardization.	Preserve scaling parameters for future model deployment.
5	Training‑validation split – Allocate 70 % for training, 15 % for validation, 15 % for testing.	Use stratified sampling if categorical surfactant types are present.

---

Building the ANN Architecture

1. Input layer – Nodes equal to the number of selected features (typically 8‑12).
2. Hidden layers – Two to three layers with 64,32,and 16 neurons respectively; employ ReLU activation to introduce non‑linearity.
3. Output layer – Single neuron for each rheological target (e.g., viscosity) with linear activation.
4. Loss function – Mean Squared Error (MSE) for regression tasks.
5. Optimizer – Adam optimizer (learning rate = 0.001) for fast convergence.

model = Sequential()


model.add(Dense(64, input_dim=n_features, activation='relu'))


model.add(Dense(32, activation='relu'))


model.add(Dense(16, activation='relu'))


model.add(Dense(1,activation='linear'))


model.compile(optimizer='adam', loss='mse')

Tip: Incorporate dropout (0.2) after each hidden layer to prevent overfitting, especially when the dataset size is limited (<200 samples).

---

Model Training, Validation, and Performance Metrics

• Early stopping – halt training when validation loss does not improve for 10 epochs.
• Cross‑validation – 5‑fold CV provides a robust estimate of generalization error.
• Key metrics:
• R² (coefficient of determination) – values > 0.90 indicate excellent predictive power.
• Root Mean Squared Error (RMSE) – compare against experimental repeatability (typically 2–5 % of measured value).
• Mean Absolute Percentage Error (MAPE) – useful for communicating accuracy to non‑technical stakeholders.

Example outcome (based on a 150‑sample dataset):

• Viscosity prediction: R² = 0.93, RMSE = 0.12 Pa·s, MAPE = 3.4 %

---

Practical Tips for Implementing ANN‑Based Rheology Prediction

• Automate data pipelines – Use Python’s pandas and scikit‑learn to streamline preprocessing.
• version control – store model architecture, weights, and scaler objects in a Git repository for reproducibility.
• Hardware considerations – Training under 10,000 epochs on a standard laptop GPU (e.g., RTX 3060) completes within 5 minutes; cloud services are optional for larger datasets.
• Integration with formulation software – Export the trained model to ONNX format, allowing it to be called from tools like Design‑Expert or MATLAB.

---

Real‑world Case Study: Predicting Thixotropic Behavior of a Diclofenac Emulgel

• Objective: Reduce experimental cycles in scaling up a 1 % diclofenac emulgel for topical pain relief.
• Dataset: 96 formulations varying in carbopol concentration (0.5‑1.5 %), oil phase (isopropyl myristate vs. medium‑chain triglycerides), and surfactant HLB (10‑14).
• Outcome: ANN predicted the yield stress with R² = 0.91; formulation optimization identified a carbopol = 1.0 % and oil = 30 % blend that met target spreadability while maintaining stability for 12 months.
• Impact: Reduced laboratory runs from 48 to 12, saving ~ 250 hours of labor and cutting material costs by 35 %.

Source: patel et al.,“Neural‑Network‑Driven Optimization of Diclofenac Emulgel Rheology,” International journal of pharmaceutics,2024.

---

Benefits of ANN Prediction for Emulgel Development

• Speed – Instantaneous property estimation once the model is trained.
• Cost Efficiency – Fewer bench experiments lower raw material and labor expenses.
• Insight Generation – Sensitivity analysis (e.g., permutation importance) reveals which formulation variables most influence viscosity or thixotropy.
• Regulatory Support – Data‑driven justification for selected formulation parameters aligns with ICH Q8(R2) guidelines on Quality by design (QbD).

---

future Directions: Integrating ANN with Multi‑Objective Optimization

1. Hybrid modeling – Combine mechanistic rheology equations (e.g., Herschel‑Bulkley model) with ANN outputs to capture both physical insight and data‑driven accuracy.
2. Multi‑task learning – Simultaneously predict viscosity,yield stress,and elastic modulus within a single network,improving efficiency and consistency.
3. Digital twin for manufacturing – Deploy the ANN model in real‑time process monitoring to adjust mixing speed or temperature on‑the‑fly, ensuring consistent product texture across batches.

---